Letrozole in Preventing Breast Cancer in Postmenopausal Women

Completed · Phase 2 · Has a placebo group

Conditions studied: Breast Cancer

In brief

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Letrozole may be effective in preventing the development or recurrence of breast cancer in postmenopausal women who are at increased risk of developing breast cancer because of elevated estradiol levels. PURPOSE: This randomized phase II trial is studying how well letrozole works in preventing breast cancer in postmenopausal women with elevated estradiol levels.

Key facts

Study ID

NCT00090857

Run by

Dana-Farber Cancer Institute

People needed

49

Starts

2002-02-01

Expected to finish

2013-03-01

Last updated by the study team

2018-03-30

Who can join

Age: 35 and older, up to 120. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Dan L. Duncan Cancer Center at Baylor College of Medicine — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.